This new report provides analysis of Elanco/Bayer’s capabilities, goals and strategies in the global animal health market, including:

- Strong technological base
- Fermentation and chemical synthesis
- Strong base in antibiotics and anticoccidials
- Expiration of patents caused restructuring
- US marketing
- Lilly Japan
- Focused marketing strategies
- Well-established relationship with customers
- Multi-disciplinary business with diverse product portfolio
- In the midst of strategic decisions
- Stepping up efforts to curtail time to market
- Could divest animal health
- Changed product mix
- Strategic collaborations
- Broadening portfolio of companion animal medicines
- Hard look at bottom line
- CEO Dave Ricks

The report also provides assessment of major U.S. and international trends with potentially significant impact on the animal health industry during the next five years, including discussion of such issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and includes five-year forecasts for:

- Major market segments
- Key geographic regions